A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Korábbi kezelés

• Patients who have previously received fulvestrant or other novel SERMs (excluding tamoxifen and toremifene);
• Participants who have not recovered from adverse effects caused by prior therapies;

Más betegség

• Patients with rapidly progressing disease, as judged by the investigator to be unsuitable for endocrine therapy;
• Patients with a history of clinically significant cardiovascular disease;
• Participants with a history of another malignancy within the past 5 years or currently having another malignancy;
• Known hypersensitivity to HRS-8080, fulvestrant, dalpiciclib, or any of their components, etc.

Egyéb

• Patients with uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression;

• Women aged 18 - 75 years old;
• Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1;
• Patients with histologically confirmed locally advanced or metastatic breast cancer;
• Patients with prior adjuvant endocrine resistance following curative-intent surgery;
• Menstrual status: postmenopausal, perimenopausal, or premenopausal;
• Presence of evaluable lesions;
• Organ function must meet required criteria.